Slovak clinical-stage biotech company Axon Neuroscience has created therapeutic antibodies able to prevent reproduction of the coronavirus (COVID-19), with the efficacy of these antibodies successfully tested in cooperation with the Virology Institute of Slovak Academy of Sciences' Bio-medical Centre, said Michael Matis from Axon Neuroscience to the Slovak News Agency on November 23.
The company has already reported positive pre-clinical results of its vaccine against COVID-19 in September, tested on mice with no adverse side effects. Now, it has launched the process of humanisation, which is a prerequisite for clinical tests.
"While developing a vaccine, we created antibodies that we used to map out the virus's weak spots. Some of them were seen to eliminate the virus completely, thereby showing their therapeutic potential. Their efficacy was proven in several conceptually distinctive tests developed at our facility," said Axon's science director Norbert Zilka, quoted by the news agency.
“We'll focus on the humanisation process as part of the next step, and then we could launch the production process,” Zilka added.
The Volkswagen plant in Bratislava plans to create 2,000 new jobs via a planned investment of €1bn, said VW Slovakia's personnel director Sebastian Krapoth at a press conference on November 16. ... ... more
The Slovak government has decided to extend the state of emergency by 45 days from November 14 until the end of the year, due to the development of the coronavirus (COVID-19) situation in the ... more
Slovakia has become the first country in the world to start the pilot stage of mass testing for coronavirus (COVID-19) in two of the most severely affected districts. A total of 140,945 ... more